UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12

BACKGROUND/AIMS: To study the effectiveness and clinical relevance of eyes treated with good (better than 6/12 or >70 Early Treatment Diabetic Retinopathy Study letters) visual acuity (VA) when initiating treatment with ranibizumab for neovascular age-related macular degeneration (nAMD) in the UK...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Ophthalmol
Egile Nagusiak: Lee, Aaron Y, Lee, Cecilia S, Butt, Thomas, Xing, Wen, Johnston, Robert L, Chakravarthy, Usha, Egan, Catherine, Akerele, Toks, McKibbin, Martin, Downey, Louise, Natha, Salim, Bailey, Clare, Khan, Rehna, Antcliff, Richard, Varma, Atul, Kumar, Vineeth, Tsaloumas, Marie, Mandal, Kaveri, Liew, Gerald, Keane, Pearse A, Sim, Dawn, Bunce, Catey, Tufail, Adnan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560462/
https://ncbi.nlm.nih.gov/pubmed/25680619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjophthalmol-2014-306229
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak